Antibody System Anti-Alirocumab ELISA Kit
This enzyme-linked immunosorbent assay (ELISA) kit is engineered for the precise quantitative determination of Anti-Alirocumab antibody concentrations in serum and plasma samples. Alirocumab is a fully human IgG1 monoclonal antibody that targets Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9). By binding to circulating PCSK9, Alirocumab prevents it from degrading low-density lipoprotein receptors (LDLR) on the surface of hepatocytes, thereby increasing the number of available receptors to clear LDL cholesterol from the bloodstream. It serves as a frontline therapeutic strategy for managing primary hyperlipidemia and heterozygous familial hypercholesterolemia. This specialized ELISA platform is optimized for detecting and quantifying anti-drug antibodies (ADAs) generated against Alirocumab, acting as a critical analytical instrument for clinical investigators, cardiologists, and pharmacologists tracking long-term therapeutic immunogenicity, analyzing secondary drug resistance, and evaluating pharmacokinetic clearance variations.
PRODUCT INFO
Principle of the Assay
This assay utilizes a high-performance, solid-phase quantitative sandwich enzyme immunoassay technique (bridging format) to measure specific anti-drug antibody levels:
-
Target Capture: Recombinant Alirocumab is uniformly pre-coated onto the solid-phase surface of a 96-well microplate.
-
Specific Binding: Calibrated standards or unknown biological samples are pipetted directly into the microwells. Endogenous Anti-Alirocumab antibodies present in the sample are bound and captured by the immobilized Alirocumab proteins.
-
Bridging Conjugation: Unbound matrix elements are removed via a rigorous wash cycle. A biotin-labeled Alirocumab tracer solution is introduced into the wells, binding to the open antigen-binding sites of the captured Anti-Alirocumab target, effectively forming an immune bridging complex.
-
Enzyme Complexing: Following another wash step to clear unbound tracer, Streptavidin conjugated to Horseradish Peroxidase (Streptavidin-HRP) is added to bind specifically to the biotinylated domains.
-
Signal Amplification and Readout: After a final wash to remove excess enzyme reagent, a colorimetric substrate solution is added to initiate enzymatic signal development. Because this is a bridging sandwich assembly, the resulting color intensity develops in direct proportion to the concentration of Anti-Alirocumab bound in the initial step. The reaction is terminated with a stop solution, and absorbance is quantified spectrophotometrically.
Key Features and Performance Metrics
-
Sensitive Detection Capability: Exhibits an analytical sensitivity down to 101.12 ng/mL, facilitating the early tracking of low-level anti-drug antibody formations.
-
Extended Quantitative Range: Delivers a wide dynamic tracking range from 156.25 ng/mL to 10,000 ng/mL to accommodate diverse sample concentration tiers without immediate saturation.
-
Exceptional Assay Precision: Demonstrates excellent target reproducibility with a Coefficient of Variation (CV) of less than 15 percent, ensuring robust experimental uniformity.
-
Reliable Recovery Profile: Validated with a target recovery range between 80 percent and 120 percent, indicating low matrix interference in both human plasma and serum testing setups.
Technical Specifications
-
Catalog No.: KAJ24001
-
Assay Configuration: Quantitative Bridging Sandwich Enzyme Immunoassay
-
Targeted Biomarker: Anti-Alirocumab (Anti-Drug Antibodies / ADA)
-
Validated Matrices: Plasma and Serum
-
Assay Range: 156.25 to 10,000 ng/mL
-
Analytical Sensitivity: 101.12 ng/mL
-
Detection Method: Colorimetric
-
Solid-Phase Target: Recombinant Alirocumab
-
Detection Enzyme Layer: Biotin-Alirocumab / Streptavidin-HRP Conjugate
Alternative Names: Anti-REGN727, Anti-SAR-236553, Anti-SAR236553, Anti-SAR 236553, Anti-CAS 1245916-14-6.
Applications and Workflow Summary
This bridging sandwich ELISA platform is highly optimized for therapeutic drug immunogenicity monitoring and downstream pharmacokinetic profiling. Investigators should observe the following guidelines:
-
Dilution and Layout: Unknown serum or plasma matrices must be screened alongside the provided reference standards. Samples exhibiting target concentrations exceeding the maximum range of 10,000 ng/mL must be diluted empirically in standard assay matrix buffer prior to running the assay.
-
Analysis Requirements: To achieve absolute quantification accuracy, investigators must generate a standard curve simultaneously during every plate run, plotting standard absorbance profiles against log-transformed concentration values.
Handling, Stability , and Storage
-
Kit Shipping: Distributed under secure, temperature-controlled conditions between 2 and 8 degrees Celsius to safeguard protein matrix and enzyme binding configurations.
-
Operational Shelf Life: Built with high-grade components to guarantee consistent, low-decay signal retention, demonstrating an activity loss rate of less than 20 percent prior to the expiration date when kept under appropriate storage conditions.
-
Storage Guidance: Keep the complete kit stored strictly at the recommended refrigeration temperature upon receipt. Ensure that unused microplate wells remain sealed within their original desiccant pouch to guard against moisture compromise.
-

















